4521 On Other Exchanges
Symbol
Exchange
4521 is not on other exchanges.

kaken pharmaceutical co ltd (4521) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)
\

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. The company operates through Pharmaceuticals and Real Estate segments. It offers pharmaceutical products and medical devices, such as Artz, an anti-osteoarthritis drug to treat knee joint pain accompanied by rheumatoid arthritis; Clenafin, a triazole anti-fungal product for topical medication of onychomycosis; Seprafilm, an anti-adhesive absorbent barrier; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing drug. The company’s pharmaceutical products and medical devices also include Regroth, a medicinal product for periodontal regeneration; Procylin to treat chronic artery occlusive diseases; Berasus to treat pulmonary arterial hypertension; Adofeed, a pain- and inflammation-relieving plaster; Mentax, a topical product used to treat superficial mycosis; and Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery, as well as generic drugs. In addition, it provides agrochemicals, including Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. Further, the company offers animal health products comprising Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Additionally, it is developing KAG-308, a Phase II clinical product to treat ulcerative colitis; KMW-1 that is preparing for clinical trial for the removal of eschar with thermal burns; and BBI-4000, a Phase II clinical product to treat primary focal hyperhidrosis. The company also rents Bunkyo Green Court commercial facility. It has a research collaboration agreement with Numab Therapeutics AG. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

1,405 Employees
Last Reported Date: 06/29/17
Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

President & Representative Director
Total Annual Compensation: ¥109.0M
Compensation as of Fiscal Year 2017.
kaken pharmaceutical co ltd
Kaken Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended of September 30, 2017; Provides Earnings Guidance for the Year Ending of March 31, 2018; Announces the Dividend for the Six Months Ended of September 30, 2017, Payable on November 30, 2017; Provides Dividend Guidance for the Year Ending of March 31, 2018

Kaken Pharmaceutical Co., Ltd. reported consolidated earnings results for the six months ended of September 30, 2017. For the period, the company reported net sales of JPY 49,860 million compared to JPY 52,179 million a year ago. Operating profit was JPY 15,335 million compared to JPY 16,123 million a year ago. Ordinary profit was JPY 15,517 million compared to JPY 16,238 million a year ago. Profit attributable to owners of parent was JPY 10,868 million compared to JPY 11,446 million a year ago. Basic earnings per share were JPY 267.56 compared to JPY 278.02. Profit before income taxes was JPY 15,481 million compared to JPY 16,173 million a year ago. Net cash provided by operating activities was JPY 11,086 million against of JPY 5,699 million a year ago. Purchase of property, plant and equipment was JPY 497 million against of JPY 1,247 million a year ago. Purchase of intangible assets was JPY 108 million against of JPY 40 million a year ago. The company provided earnings guidance for the year ending of March 31, 2018. For the period, the company expects net sales to be of JPY 101,700 million. Operating profit expected to be of JPY 26,800 million. Ordinary profit expected to be of JPY 27,000 million. Profit attributable to owners of parent expected to be of JPY 19,100 million. Basic earnings per share expected to be of JPY 473.70. The company announced the dividend for the six months ended of September 30, 2017. For the period, the company announced the dividend of JPY 75.00 per share compared to JPY 75.00 per share a year ago. The dividend will be payable on November 30, 2017. The company provides dividend guidance for the year ending of March 31, 2018. For the period, the company provides dividend guidance of JPY 75.00 per share compared to JPY 75.00 per share a year ago.

Kaken Pharmaceutical Co., Ltd., Q2 2018 Earnings Call, Nov 08, 2017

Kaken Pharmaceutical Co., Ltd., Q2 2018 Earnings Call, Nov 08, 2017

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2018 Results on Nov 06, 2017

Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2018 results on Nov 06, 2017

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies
 

Industry Analysis

4521

Industry Average

Valuation 4521 Industry Range
Price/Earnings 11.1x
Price/Sales 2.4x
Price/Book 2.2x
Price/Cash Flow 13.0x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KAKEN PHARMACEUTICAL CO LTD, please visit www.kaken.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.